← Scoopfeeds — Intelligent news, curated.
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
business

Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death

Bloomberg Markets · Apr 28, 2026, 5:23 PM · Also reported by 2 other sources

Erasca Inc. shares plunged as much as 55% Tuesday after the cancer-drug developer said one patient withdrew from its clinical trial and later died after suffering severe side effects related to the treatment.

Read full story on Bloomberg Markets → More top stories

Also covered by

NY Times F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer CNBC AstraZeneca stock falls after FDA panel votes against new cancer drug

More in business

Bloomberg Markets
Fresh Concerns for Private Credit As Milken Looms
CNBC
The market isn't grading all Big Tech earnings the same — here's why
Bloomberg Markets
Brown University Slashed Stake in Blue Owl Private Credit Fund
Forbes
LSU Teammates Mansoor Delane And Garrett Nussmeier Practice As Chiefs For First Time
Fast Company
Spirit’s collapse could hit overnight and your next trip is on the line
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop